Netellis

Netellis is a clinical-stage biotechnology company focused on developing and commercializing innovative therapies for women's health. The company's lead product candidate, NTL-101, is a potent and selective non-hormonal neurokinin 3 (NK3) receptor antagonist being developed for the treatment of vasomotor symptoms (VMS) associated with menopause. NTL-101, formerly known as MLE-301, was acquired by Netellis and is currently in Phase 2 clinical trials. Netellis aims to address the significant unmet medical need for safe and effective non-hormonal options for women experiencing hot flashes and night sweats. The company is headquartered in San Diego, California, and is led by a management team with extensive experience in the women's health and endocrine therapeutic areas.